TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
BioArctic AB Class B ( ($SE:BIOA.B) ) has provided an update.
BioArctic AB reported its Q3 2025 interim results, highlighting a significant increase in net revenues driven by royalties from its Alzheimer’s treatment, Leqembi, and a new agreement with Novartis. Despite the revenue growth, the company faced a loss for the period, reflecting ongoing investments in research and development. Key achievements include regulatory approvals and launches of Leqembi in multiple countries, enhancing BioArctic’s market presence and potential future revenue streams.
The most recent analyst rating on ($SE:BIOA.B) stock is a Buy with a SEK328.00 price target. To see the full list of analyst forecasts on BioArctic AB Class B stock, see the SE:BIOA.B Stock Forecast page.
More about BioArctic AB Class B
BioArctic AB is a biopharmaceutical company focused on developing innovative treatments for neurodegenerative diseases, particularly Alzheimer’s disease. The company leverages its proprietary BrainTransporter technology and collaborates with major pharmaceutical firms to enhance its product offerings.
Average Trading Volume: 310,839
Technical Sentiment Signal: Buy
Current Market Cap: SEK23.61B
For an in-depth examination of BIOA.B stock, go to TipRanks’ Overview page.